Download Files:
GSK2245035
$330 – $1,980
Products Details
Product Description
– GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma[1].
Web ID
– HY-118250
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C20H34N6O2
References
– [1]Biggadike K, et al. Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma. J Med Chem. 2016 Mar 10;59(5):1711-26.
CAS Number
– 1207629-49-9
Molecular Weight
– 390.52
Compound Purity
– 99.85
SMILES
– O=C1NC2=C(N=C(N=C2N1CCCCCN3CCCCC3)O[C@H](CCC)C)N
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– IFNAR;TNF Receptor;Toll-like Receptor (TLR)
Isoform
– CD40;TLR7
Pathway
– Apoptosis;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
